Bioequivalence evaluation and food effect assessment of Lisinopril/amlodipine tablets in healthy Chinese subjects under fasting and fed conditions

Ting Li, Yan-Ping Liu, Shu-Qin Liu, Ping Shi, Xin Jiang, Ye Tao, Xiao-Meng Gao, Ya-Ping Ma, Yu Cao, Ting Li, Yan-Ping Liu, Shu-Qin Liu, Ping Shi, Xin Jiang, Ye Tao, Xiao-Meng Gao, Ya-Ping Ma, Yu Cao

Abstract

Purpose: The combination of lisinopril and amlodipine has a marked additional effect on blood pressure and fewer side effects than individual monotherapy. This study was conducted to compare the pharmacokinetic parameters and evaluate the bioequivalence between two Lisinopril/amlodipine tablets in healthy Chinese subjects.

Methods: A single center, randomized, open-label, single-dose, two-period crossover bioequivalence study was designed in healthy Chinese subjects under both fasting and fed conditions. Blood samples were collected before drug administration and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 24, 36, 48, 72, 96, 144, 168 h after administration. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was applied to determine the plasma concentration of lisinopril and amlodipine. Maximum concentration (Cmax) and area under the concentration-time curve (AUC) were used to evaluate bioequivalence. Adverse events were recorded.

Results: Ninety-two healthy subjects were enrolled, and 75 completed the study. The 90% confidence intervals (CIs) of the ratio of geometric means (GMRs) of Cmax, AUC0-t, and AUC0-∞ of lisinopril and amlodipine under both fasting and fed conditions fell within the conventional bioequivalence criteria of 0.80-1.25. A high-fat meal appeared to decrease the Cmax and AUC of lisinopril. No severe adverse events were observed.

Conclusion: The trial demonstrated that the test and the reference lisinopril/amlodipine tablets were bioequivalent and well tolerated in Chinese people under fasting and fed conditions.

Trial registration: Clinical Trails.gov identifier, NCT04885660 (retrospectively registered in 13/05/ 2021).

Keywords: Amlodipine; Bioequivalence; Food effect; Lisinopril; Pharmacokinetic.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
The study flow diagram
Fig. 2
Fig. 2
Mean plasma concentration versus time profiles of lisinopril (A), amlodipine (B) under fasting conditions and lisinopril (C), amlodipine (D) under fed conditions, following a single dose of the test and reference Lisinopril/amlodipine tablets in Chinese subjects
Fig. 3
Fig. 3
Mean (A) systolic blood pressure (SBP), (B) diastolic blood pressure (DBP) under fasting condition and mean (C) SBP, (D) DBP under fed condition following a single administration of test and reference Lisinopril/amlodipine tablets in Chinese subjects

References

    1. Williams B, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1177/1747493018778713.
    1. China, T.W.C.o.t.R.o.C.H.D.i., Annual report on cardiovascular health and diseases in China 2019. Chin Circ J, 2020 35(09):833–854.10.3969/j.issn.1000-3614.202
    1. Wang Z, et al. Status of Hypertension in China: results from the China Hypertension Survey, 2012-2015. Circulation. 2018;137(22):2344–2356. doi: 10.1161/CIRCULATIONAHA.117.032380.
    1. Joint Committee for Guideline R. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2019;16(3):182–241. doi: 10.11909/j.issn.1671-5411.2019.03.014.
    1. Canbakan B. Rational approaches to the treatment of hypertension: drug therapy-monotherapy, combination, or fixed-dose combination? Kidney Int Suppl (2011) 2013;3(4):349–351. doi: 10.1038/kisup.2013.75.
    1. Brunner DB, et al. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol. 1981;11(5):461–467. doi: 10.1111/j.1365-2125.1981.tb01151.x.
    1. Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207–224. doi: 10.2165/00003088-200241030-00005.
    1. Tamimi JJ, et al. Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers. Biopharm Drug Dispos. 2005;26(8):335–339. doi: 10.1002/bdd.465.
    1. Georgarakis M, et al. Evaluation of the bioequivalence and pharmacokinetics of two lisinopril tablet formulations after single oral administration in healthy volunteers. Arzneimittelforschung. 2004;54(1):15–19. doi: 10.1055/s-0031-1296931.
    1. Shin MC, Kim JK, Kim CK. Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test. Arzneimittelforschung. 2008;58(1):11–17. doi: 10.1055/s-0031-1296460.
    1. Beermann B, et al. Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. Biopharm Drug Dispos. 1989;10(4):397–409. doi: 10.1002/bdd.2510100407.
    1. Zhu Y, et al. Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug MetabDispos. 2014;42(2):245–249. doi: 10.1124/dmd.113.055400.
    1. Li X, et al. Bioequivalence of levamlodipine besylate tablets in healthy Chinese subjects: a single-dose and two-period crossover randomized study. BMC PharmacolToxicol. 2020;21(1):80. doi: 10.1186/s40360-020-00459-6.
    1. Wang T, et al. Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings. J Clin Lab Anal. 2020;34(6):e23228.
    1. Naidu MU, et al. Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension. Postgrad Med J. 2000;76(896):350–353. doi: 10.1136/pmj.76.896.350.
    1. Galeeva ZM, Galiavich AS. A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease. Ter Arkh. 2014;86(9):71–76.
    1. U.S. Food and Drug Administration. Zestril (lisinopril) Clinical pharmacology and Biopharmaceutics reviews.
    1. Mojaverian P, et al. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. J Pharm Sci. 1986;75(4):395–397. doi: 10.1002/jps.2600750416.
    1. Deng J, et al. A Review of Food-Drug Interactions on Oral Drug Absorption. Drugs. 2017;77(17):1833–1855. doi: 10.1007/s40265-017-0832-z.
    1. Berg W. Metabolism and pathophysiology of oxalic acid. Z Urol Nephrol. 1990;83(9):481–488.
    1. Thind GS. Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics. Cardiovasc Drugs Ther. 1990;4(1):199–206. doi: 10.1007/BF01857634.
    1. Lecocq B, et al. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin PharmacolTher. 1990;47(3):397–402. doi: 10.1038/clpt.1990.45.
    1. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23. doi: 10.1007/s11095-004-9004-4.
    1. Ulm EH, et al. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982;14(3):357–362. doi: 10.1111/j.1365-2125.1982.tb01991.x.
    1. Vandenburg MJ, et al. A study of the potential pharmacokinetic interaction of lisinopril and digoxin in normal volunteers. Xenobiotica. 1988;18(10):1179–1184. doi: 10.3109/00498258809042240.
    1. Lees KR, Reid JL. Lisinopril and nifedipine: no acute interaction in normotensives. Br J Clin Pharmacol. 1988;25(3):307–313. doi: 10.1111/j.1365-2125.1988.tb03308.x.
    1. Koytchev R, et al. Effect of the combination of lisinopril and hydrochlorothiazide on the bioequivalence of tablet formulations. Arzneimittelforschung. 2004;54(9A):605–610. doi: 10.1055/s-0031-1297057.
    1. Gautam PC, Vargas E, Lye M. Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure. J Pharm Pharmacol. 1987;39(11):929–931. doi: 10.1111/j.2042-7158.1987.tb03130.x.
    1. Misaka S, et al. Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers. Clin Transl Sci. 2021;14(2):476–480. doi: 10.1111/cts.12905.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj